4Front Ventures (4Front Ventures) Risk Assessment

View and export this data going back to 2010. Start your Free Trial

What is 4Front Ventures Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of 4Front Ventures is: High Risk: High uncertainty.

Competitive Comparison of 4Front Ventures's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, 4Front Ventures's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

4Front Ventures's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, 4Front Ventures's Risk Assessment distribution charts can be found below:

* The bar in red indicates where 4Front Ventures's Risk Assessment falls into.

4Front Ventures (OTCPK:FFNTF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

4Front Ventures Risk Assessment Related Terms

Thank you for viewing the detailed overview of 4Front Ventures's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

4Front Ventures (4Front Ventures) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » 4Front Ventures Corp (OTCPK:FFNTF) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

FFNT:Canada

Address

5060 North 40th Street, Suite 120, Phoenix, AZ, USA, 85018

Website

https://www.4frontventures.com

4Front Ventures Corp is a Canadian-based company. It is engaged in the cultivation, processing, extracting, manufacturing, and distribution of cannabis products. It operates in two segments: THC Cannabis and CBD Wellness. The THC Cannabis segment engages in the production and cultivation of THC cannabis, manufacturing and distribution of cannabis products to own dispensaries and third-party retail customers. The CBD Wellness segment encompasses the production and sale of CBD products to third-party customers.

Executives

Leonid Gontmakher	director, officer: Chief Executive Officer	5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
Nicole Frederick	officer: See Remarks	C/O 4FRONT VENTURES CORP., 7010 E. CHAUNCEY LANE STE. 235, PHOENIX AZ 85054
Kristopher Krane	director	5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
David Ryan Daily	director	5060 N 40TH STREET STE 120, PHOENIX AZ 85018
Roman Tkachenko	director	5060 N 40TH STREET STE 120, PHOENIX AZ 85018
Karl Chowscano	other: Consultant	5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
Chetan Gulati	director	28 REICHERT CIRCLE, WESTPORT CT 06880
Keith Edward Adams	officer: Chief Financial Officer	108 S. WETHERLY DRIVE, UNIT 4, LOS ANGELES CA 90048
Robert E Hunt	director	C/O GROWLIFE, INC., 20301 VENTURA BLVD., SUITE 126, WOODLAND HILLS CA 91364
Amit Ramanlal Patel	director	3305 PINE AVENUE, MANHATTAN BEACH CA 90266
Kathi P Lentzsch	director	5060 N 40TH STREET STE 120, PHOENIX AZ 85018
Andrew Thut	officer: Chief Investment Officer	5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
Joseph R Feltham	officer: Chief Operating Officer	5060 N. 40TH STREET, STE 120, PHOENIX AZ 85018
Eric J. Rey	director	ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Nicolle Dorsey	officer: Chief Financial Officer	C/O REAL GOODS SOLAR, INC., 110 16TH STREET, 3RD FLOOR, DENVER CO 80202